Clinical Trial Update: A Trial of PF-06252616 in Ambulatory Participants With LGMD2I [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial of PF-06252616 in ambulatory participants with LGMD2I has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-girdle Muscular Dystrophy Type 2i

Drugs mentioned

• PF-06252616

Snippet

Sponsor: Kathryn Wagner | Conditions: LGMD2I | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-10-19